BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19146898)

  • 1. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys.
    Fu TM; Grimm KM; Citron MP; Freed DC; Fan J; Keller PM; Shiver JW; Liang X; Joyce JG
    Vaccine; 2009 Feb; 27(9):1440-7. PubMed ID: 19146898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.
    Fan J; Liang X; Horton MS; Perry HC; Citron MP; Heidecker GJ; Fu TM; Joyce J; Przysiecki CT; Keller PM; Garsky VM; Ionescu R; Rippeon Y; Shi L; Chastain MA; Condra JH; Davies ME; Liao J; Emini EA; Shiver JW
    Vaccine; 2004 Aug; 22(23-24):2993-3003. PubMed ID: 15297047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein.
    Ravin NV; Kotlyarov RY; Mardanova ES; Kuprianov VV; Migunov AI; Stepanova LA; Tsybalova LM; Kiselev OI; Skryabin KG
    Biochemistry (Mosc); 2012 Jan; 77(1):33-40. PubMed ID: 22339631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
    Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
    J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A "universal" human influenza A vaccine.
    Fiers W; De Filette M; Birkett A; Neirynck S; Min Jou W
    Virus Res; 2004 Jul; 103(1-2):173-6. PubMed ID: 15163506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus.
    Fu TM; Freed DC; Horton MS; Fan J; Citron MP; Joyce JG; Garsky VM; Casimiro DR; Zhao Q; Shiver JW; Liang X
    Virology; 2009 Mar; 385(1):218-26. PubMed ID: 19070878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal influenza A vaccine: optimization of M2-based constructs.
    De Filette M; Min Jou W; Birkett A; Lyons K; Schultz B; Tonkyro A; Resch S; Fiers W
    Virology; 2005 Jun; 337(1):149-61. PubMed ID: 15914228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.
    Liu W; Zou P; Chen YH
    Immunol Lett; 2004 May; 93(2-3):131-6. PubMed ID: 15158608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
    De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
    Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A universal influenza A vaccine based on the extracellular domain of the M2 protein.
    Neirynck S; Deroo T; Saelens X; Vanlandschoot P; Jou WM; Fiers W
    Nat Med; 1999 Oct; 5(10):1157-63. PubMed ID: 10502819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved design and intranasal delivery of an M2e-based human influenza A vaccine.
    De Filette M; Fiers W; Martens W; Birkett A; Ramne A; Löwenadler B; Lycke N; Jou WM; Saelens X
    Vaccine; 2006 Nov; 24(44-46):6597-601. PubMed ID: 16814430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble recombinant influenza vaccines.
    Fiers W; Neirynck S; Deroo T; Saelens X; Jou WM
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1961-3. PubMed ID: 11779398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.
    Zou P; Liu W; Chen YH
    Int Immunopharmacol; 2005 Apr; 5(4):631-5. PubMed ID: 15710332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus.
    Zhang YL; Guo YJ; Wang KY; Lu K; Li K; Zhu Y; Sun SH
    Scand J Immunol; 2007 Apr; 65(4):320-8. PubMed ID: 17386022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens.
    Pütz MM; Ammerlaan W; Schneider F; Jung G; Muller CP
    Vaccine; 2004 Oct; 22(31-32):4173-82. PubMed ID: 15474707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody recognizing SLLTEVET epitope of M2 protein potently inhibited the replication of influenza A viruses in MDCK cells.
    Wang Y; Zhou L; Shi H; Xu H; Yao H; Xi XG; Toyoda T; Wang X; Wang T
    Biochem Biophys Res Commun; 2009 Jul; 385(1):118-22. PubMed ID: 19410554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.